Maravai LifeSciences (NASDAQ:MRVI) Trading 9.5% Higher – Should You Buy?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)’s stock price rose 9.5% during trading on Tuesday . The stock traded as high as $5.19 and last traded at $5.23. Approximately 1,393,068 shares were traded during trading, a decline of 33% from the average daily volume of 2,088,515 shares. The stock had previously closed at $4.77.

Analyst Ratings Changes

MRVI has been the subject of several analyst reports. Guggenheim began coverage on shares of Maravai LifeSciences in a research note on Thursday, December 19th. They set a “neutral” rating for the company. Robert W. Baird cut their target price on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. The Goldman Sachs Group lowered Maravai LifeSciences from a “neutral” rating to a “sell” rating and reduced their price target for the company from $7.00 to $4.25 in a research report on Thursday, December 5th. William Blair restated a “market perform” rating on shares of Maravai LifeSciences in a research report on Friday, November 8th. Finally, Royal Bank of Canada reduced their target price on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $10.28.

Maravai LifeSciences Stock Performance

The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -3.43 and a beta of -0.07. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. The company has a 50 day simple moving average of $5.36 and a 200-day simple moving average of $7.27.

Maravai LifeSciences (NASDAQ:MRVI) last issued its earnings results on Thursday, November 7th. The company reported ($0.09) earnings per share (EPS) for the quarter. Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. The company had revenue of $65.20 million for the quarter, compared to the consensus estimate of $67.58 million. During the same period in the prior year, the company earned ($0.02) earnings per share. As a group, equities research analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current fiscal year.

Insider Activity

In other news, insider Carl Hull bought 175,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were bought at an average cost of $5.64 per share, for a total transaction of $987,000.00. Following the acquisition, the insider now directly owns 175,000 shares in the company, valued at approximately $987,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.63% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Creative Planning grew its holdings in shares of Maravai LifeSciences by 4.4% during the third quarter. Creative Planning now owns 44,943 shares of the company’s stock valued at $373,000 after buying an additional 1,881 shares during the last quarter. SG Americas Securities LLC boosted its stake in Maravai LifeSciences by 7.3% during the 4th quarter. SG Americas Securities LLC now owns 33,046 shares of the company’s stock valued at $180,000 after purchasing an additional 2,239 shares during the last quarter. Kornitzer Capital Management Inc. KS increased its holdings in Maravai LifeSciences by 0.7% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 519,890 shares of the company’s stock worth $4,320,000 after purchasing an additional 3,725 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Maravai LifeSciences in the second quarter worth approximately $32,000. Finally, Venturi Wealth Management LLC bought a new position in shares of Maravai LifeSciences in the third quarter valued at approximately $47,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.